NCT03189563View on ClinicalTrials.gov

Safety and Efficacy of DA-9805 for Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

April 10, 2019

Study Completion Date

April 10, 2019

Conditions
Parkinson's Disease
Interventions
DRUG

DA-9805 45mg

DA-9805 15mg tid

DRUG

DA-9805 90mg

DA-9805 30mg tid

OTHER

Placebo

Placebo, tid

Trial Locations (1)

55425

HealthPartners Institute, Bloomington

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT03189563 - Safety and Efficacy of DA-9805 for Parkinson's Disease | Biotech Hunter | Biotech Hunter